Company news

Sernova Biotherapeutics Inc news in 2022

Sernova Biotherapeutics Inc's news releases, calls and decks from 2022, newest first.

View company

Sernova Corp. Announces Change of Auditor

October 24, 2022

Sernova Opens the Market

June 2, 2022

SERNOVA SHARES to Commence Trading on TSX On June 2, 2022

June 1, 2022

Sernova Receives Conditional Approval to Up-list to the Toronto Stock Exchange

May 24, 2022

Sernova Announces Abstract on Phase 1/2 Trial with Cell Pouch Selected for Oral Podium Presentation at American Diabetes Association 82nd Scientific Sessions 2022

May 9, 2022

Sernova to Participate in Multiple U.S. Healthcare Investor Conferences

May 5, 2022

Sernova Announces 2022 Annual General Meeting Results

April 29, 2022

Data Safety Monitoring Board Recommends Continuation of Phase 1/2 Clinical Trial with Sernova's Cell Pouch System(TM) in Patients with Type-1 Diabetes

March 17, 2022

Sernova Corp Ranks Among Top 50 Performing Companies on the 2022 TSX Venture List

February 24, 2022

Sernova Announces Peer Reviewed Publication Demonstrating Positive Preclinical Safety and Efficacy Indicators of Its Novel Cell Pouch System(TM) Therapeutic Approach for Treatment of Thyroid Disease

January 27, 2022

Sernova Announces Peer Reviewed Publication Demonstrating Safety and Efficacy of a Novel Cell Pouch Cell Therapy Approach for Treatment of Severe Hemophilia A

January 20, 2022

The Principal Investigator in Sernova's Type 1 Diabetes (T1D) Trial Confirms Patients with a History of Hypoglycemia Unawareness Are Now Insulin Independent

January 10, 2022

Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual J.P. Morgan Healthcare Conference

January 5, 2022

Decks in 2022